118 related articles for article (PubMed ID: 38095514)
1. Harnessing p53 to improve immunotherapy for lung cancer treatment.
Niu X; Martinez L
Cancer Res; 2023 Dec; ():. PubMed ID: 38095514
[TBL] [Abstract][Full Text] [Related]
2. Harnessing p53 to Improve Immunotherapy for Lung Cancer Treatment.
Niu X; Martinez L
Cancer Res; 2023 Dec; ():OF1-OF2. PubMed ID: 38128037
[TBL] [Abstract][Full Text] [Related]
3. Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
Zhu M; Kim J; Deng Q; Ricciuti B; Alessi JV; Eglenen-Polat B; Bender ME; Huang HC; Kowash RR; Cuevas I; Bennett ZT; Gao J; Minna JD; Castrillon DH; Awad MM; Xu L; Akbay EA
Cancer Cell; 2023 Oct; 41(10):1731-1748.e8. PubMed ID: 37774698
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
5. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
6. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
7. Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.
Yang RK; Qing Y; Jelloul FZ; Routbort MJ; Wang P; Shaw K; Zhang J; Lee J; Medeiros LJ; Kopetz S; Tetzlaff MT; Broaddus RR
Oncotarget; 2020 Feb; 11(6):600-618. PubMed ID: 32110280
[TBL] [Abstract][Full Text] [Related]
8. A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.
Pan D; Hu AY; Antonia SJ; Li CY
J Thorac Oncol; 2021 Mar; 16(3):419-427. PubMed ID: 33307194
[TBL] [Abstract][Full Text] [Related]
9. Mutations in
Liu D; Benzaquen J; Morris LGT; Ilié M; Hofman P
Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681795
[TBL] [Abstract][Full Text] [Related]
10. A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response.
Weir WH; Mucha PJ; Kim WY
Cell Rep Med; 2022 May; 3(5):100602. PubMed ID: 35584624
[TBL] [Abstract][Full Text] [Related]
11. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
12. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
[TBL] [Abstract][Full Text] [Related]
13. Mutational burden and immune recognition of gliomas.
Prost D; Bielle F; Ligon KL; Touat M
Curr Opin Oncol; 2021 Nov; 33(6):626-634. PubMed ID: 34651608
[TBL] [Abstract][Full Text] [Related]
14. Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
Kim J; Kim B; Kang SY; Heo YJ; Park SH; Kim ST; Kang WK; Lee J; Kim KM
Front Oncol; 2020; 10():314. PubMed ID: 32232003
[No Abstract] [Full Text] [Related]
15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.
Westcott PMK; Muyas F; Hauck H; Smith OC; Sacks NJ; Ely ZA; Jaeger AM; Rideout WM; Zhang D; Bhutkar A; Beytagh MC; Canner DA; Jaramillo GC; Bronson RT; Naranjo S; Jin A; Patten JJ; Cruz AM; Shanahan SL; Cortes-Ciriano I; Jacks T
Nat Genet; 2023 Oct; 55(10):1686-1695. PubMed ID: 37709863
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
[TBL] [Abstract][Full Text] [Related]
18. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center.
Rosenbaum E; Antonescu CR; Smith S; Bradic M; Kashani D; Richards AL; Donoghue M; Kelly CM; Nacev B; Chan JE; Chi P; Dickson MA; Keohan ML; Gounder MM; Movva S; Avutu V; Thornton K; Zehir A; Bowman AS; Singer S; Tap W; D'Angelo S
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365586
[TBL] [Abstract][Full Text] [Related]
19. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
[TBL] [Abstract][Full Text] [Related]
20. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
